• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

Introduction to 2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid (CAS No. 1005631-80-0)

2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid, identified by its CAS number 1005631-80-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and chemical synthesis. This compound belongs to the pyrazole derivatives, a class of heterocyclic compounds known for their diverse biological activities and potential applications in drug development. The structural features of this molecule, including the presence of bromine, difluoromethyl, and methyl substituents, contribute to its unique chemical properties and make it a valuable scaffold for further functionalization and study.

The pyrazol-1-ylpropanoic acid moiety in the name highlights the core structure of the compound, which is characterized by a six-membered aromatic ring containing two nitrogen atoms. This pyrazole ring is a common pharmacophore in medicinal chemistry, often found in drugs with anti-inflammatory, antiviral, and anticancer properties. The introduction of bromine atoms at the 2 and 4 positions enhances the electrophilicity of the ring, making it more reactive in various chemical transformations. Additionally, the difluoromethyl group at the 3-position introduces electron-withdrawing effects, which can influence the electronic properties of the molecule and its interactions with biological targets.

The 5-methyl substituent further modifies the electronic environment of the pyrazole ring, potentially affecting its binding affinity and metabolic stability. These structural elements collectively contribute to the compound's versatility as a building block in synthetic chemistry. In recent years, there has been growing interest in developing novel pyrazole derivatives for therapeutic applications, particularly due to their ability to modulate various biological pathways.

One of the most compelling aspects of 2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid is its potential as an intermediate in the synthesis of more complex pharmacological agents. Researchers have been exploring its utility in generating novel molecules with enhanced pharmacological profiles. For instance, studies have demonstrated that pyrazole derivatives can serve as inhibitors of enzymes involved in inflammatory processes. The bromine and difluoromethyl groups provide handles for further chemical modifications, allowing chemists to tailor the molecule's properties for specific biological targets.

Recent advancements in computational chemistry have also facilitated the design of new derivatives based on this scaffold. By leveraging molecular modeling techniques, scientists can predict how modifications to the pyrazol-1-ylpropanoic acid core will affect its binding affinity and selectivity. This approach has led to the identification of several promising candidates for further experimental validation. The combination of experimental synthesis and computational analysis provides a powerful framework for optimizing drug-like properties.

In addition to its role as a synthetic intermediate, 2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid has been investigated for its potential bioactivity. Preliminary studies suggest that this compound may exhibit inhibitory effects on certain kinases and other enzymes implicated in cancer progression. The presence of multiple substituents allows for fine-tuning of its activity profile, making it a promising candidate for development into an anticancer therapeutic. Furthermore, its structural features may contribute to improved solubility and bioavailability compared to simpler pyrazole derivatives.

The pharmaceutical industry has long recognized the importance of heterocyclic compounds in drug discovery. Pyrazoles, in particular, have been extensively studied due to their broad range of biological activities. The introduction of electron-withdrawing groups such as difluoromethyl enhances their potency by improving interactions with biological targets. The bromine atoms further enhance reactivity, enabling diverse synthetic pathways that can be exploited to generate novel analogs.

One area where this compound shows promise is in the development of antiviral agents. Viruses often rely on specific enzymes for replication, and inhibitors targeting these enzymes can effectively prevent viral propagation. Pyrazole derivatives have demonstrated efficacy against various viral strains due to their ability to disrupt essential enzymatic processes. The unique structural features of 2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid make it an attractive candidate for designing next-generation antiviral drugs.

Another emerging application is in immunomodulation. Chronic inflammation is a hallmark of many diseases, including autoimmune disorders and metabolic syndromes. Compounds that can modulate inflammatory pathways offer significant therapeutic potential. Pyrazole derivatives have been shown to inhibit key pro-inflammatory cytokines and enzymes, making them valuable candidates for treating inflammatory conditions.

The synthesis of 2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include halogenation reactions followed by functional group interconversions. Advances in green chemistry have also led to more sustainable methods for producing these compounds, reducing waste and minimizing environmental impact.

In conclusion,2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylopropanoic acid (CAS No. 1005631–80–0) represents a significant advancement in pharmaceutical chemistry due to its versatile structural framework and potential bioactivity。 Its role as a synthetic intermediate enables the development of novel therapeutic agents targeting various diseases。 As research continues，this compound is likely to play an increasingly important role in drug discovery and development，offering new hope for treating some of today's most challenging medical conditions。

• 1005566-34-6(2-[5-methyl-3-(trifluoromethyl)-1h-pyrazol-1-yl]propanoic Acid)
• 354989-32-5(ethyl 2-4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetate)
• 1001500-11-3(2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetic acid)
• 1005584-44-0(2-[4-bromo-5-methyl-3-(trifluoromethyl)-1h-pyrazol-1-yl]propanoic Acid)
• 1001518-85-9(3-[4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]propanoic acid)
• 1005586-13-9(2-3,5-bis(difluoromethyl)-1H-pyrazol-1-ylpropanoic acid)
• 925200-46-0(2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propanoic acid)
• 1006320-26-8(2-4-Bromo-5-cyclopropyl-3-(trifluoromethyl)pyrazol-1-ylpropanoic acid)
• 60061-73-6(2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)propanoic acid)
• 299405-26-8(2-4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic acid)